Frontal Gamma Coherence Neurofeedback for Patients With Schizophrenia

This preliminary, randomized, double-blind, placebo-controlled clinical trial will evaluate frontal gamma coherence neurofeedback in adults with schizophrenia. Thirty participants will be randomly assigned to receive either active neurofeedback or placebo neurofeedback using a study-provided mobile platform. Participants will complete baseline assessments in person at the University of California San Diego, receive training on home use of the neurofeedback platform, and complete twice-weekly 30-minute sessions at home for 12 weeks. Participants will return for midpoint and end-of-treatment assessments to evaluate feasibility, tolerability, cognitive outcomes, and neurophysiological target engagement.

NCT Number	NCT07659938
Lead Sponsor	BioSignal Solutions LLC Collaborators: National Institute of Mental Health (NIMH), University of California, San Diego
Conditions	Schizophrenia, Schizoaffective
Enrollment	30 participants
Start Date	2027-04
Primary Completion	2028-06 (estimated)
Study Completion	2028-06 (estimated)
Updated on ClinicalTrials.gov	2026-06-22